TY - JOUR
T1 - High-risk breast cancer surveillance with MRI
T2 - 10-year experience from the German consortium for hereditary breast and ovarian cancer
AU - the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
AU - Bick, Ulrich
AU - Engel, Christoph
AU - Krug, Barbara
AU - Heindel, Walter
AU - Fallenberg, Eva M.
AU - Rhiem, Kerstin
AU - Maintz, David
AU - Golatta, Michael
AU - Speiser, Dorothee
AU - Rjosk-Dendorfer, Dorothea
AU - Lämmer-Skarke, Irina
AU - Dietzel, Frederic
AU - Schäfer, Karl Werner Fritz
AU - Leinert, Elena
AU - Weigel, Stefanie
AU - Sauer, Stephanie
AU - Pertschy, Stefanie
AU - Hofmockel, Thomas
AU - Hagert-Winkler, Anne
AU - Kast, Karin
AU - Quante, Anne
AU - Meindl, Alfons
AU - Kiechle, Marion
AU - Loeffler, Markus
AU - Schmutzler, Rita K.
AU - Blohmer, Jens Uwe
AU - Horn, Denise
AU - Varon-Mateeva, Raymonda
AU - Hübbel, Verena
AU - Herold, Natalie
AU - Püsken, Michael
AU - Wimberger, Pauline
AU - Meisel, Cornelia
AU - Keller, Katja
AU - Antoch, Gerald
AU - Vesper, Anne Sophie
AU - Fehm, Tanja N.
AU - Schlegelberger, Brigitte
AU - Auber, Bernd
AU - Wallaschek, Hannah
AU - Heil, Jörg
AU - Schott, Sarah
AU - Dikow, Nicola
AU - Mundhenke, Christoph
AU - Arnold, Norbert
AU - Caliebe, Almuth
AU - Briest, Susanne
AU - Lemke, Johannes
AU - Gril, Sabine
AU - Pfeifer, Katharina
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Purpose: To report on 10 years of high-risk service screening with annual MRI in the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods: A cohort of 4,573 high-risk, previously unaffected women (954 BRCA1 carriers, 598 BRCA2 carriers, 3021 BRCA1/2 non-carriers) participating in the GC-HBOC surveillance program was prospectively followed. Screening outcomes for 14,142 screening rounds with MRI between 2006 and 2015 were analyzed and stratified by risk group, type of screening round, and age. Results: A total of 221 primary breast cancers (185 invasive, 36 in situ) were diagnosed within 12 months of an annual screening round with MRI. Of all cancers, 84.5% (174/206, 15 unknown) were stage 0 or I. In BRCA1 carriers, 16.9% (10/59, 5 unknown) of all incident cancers (screen-detected and interval cancers combined) and in BRCA2 carriers 12.5% (3/24, 4 unknown) were stage IIA or higher, compared to only 4.8% (2/42, 2 unknown) in high-risk BRCA1/2 non-carriers. Program sensitivity was 89.6% (95% CI 84.9–93.0) with no significant differences in sensitivity between risk groups or by age. Specificity was significantly lower in the first screening round (84.6%, 95% CI 83.6–85.7) than in subsequent screening rounds (91.1%, 95% CI 90.6–91.7), p < 0.001. Cancer detection rates (CDRs) and as a result positive predictive values were strongly dependent on type of screening round, risk group and patient age. CDRs ranged from 43.5‰ (95% CI 29.8–62.9) for the first screening round in BRCA2 carriers to 2.9‰ (95% CI 1.3–6.3) for subsequent screening rounds in high-risk non-carriers in the age group 30 to 39 years. Conclusions: High-risk screening with MRI was successfully implemented in the GC-HBOC with high sensitivity and specificity. Risk prediction and inclusion criteria in high-risk non-carriers need to be adjusted to improve CDRs and thus screening efficacy in these patients.
AB - Purpose: To report on 10 years of high-risk service screening with annual MRI in the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods: A cohort of 4,573 high-risk, previously unaffected women (954 BRCA1 carriers, 598 BRCA2 carriers, 3021 BRCA1/2 non-carriers) participating in the GC-HBOC surveillance program was prospectively followed. Screening outcomes for 14,142 screening rounds with MRI between 2006 and 2015 were analyzed and stratified by risk group, type of screening round, and age. Results: A total of 221 primary breast cancers (185 invasive, 36 in situ) were diagnosed within 12 months of an annual screening round with MRI. Of all cancers, 84.5% (174/206, 15 unknown) were stage 0 or I. In BRCA1 carriers, 16.9% (10/59, 5 unknown) of all incident cancers (screen-detected and interval cancers combined) and in BRCA2 carriers 12.5% (3/24, 4 unknown) were stage IIA or higher, compared to only 4.8% (2/42, 2 unknown) in high-risk BRCA1/2 non-carriers. Program sensitivity was 89.6% (95% CI 84.9–93.0) with no significant differences in sensitivity between risk groups or by age. Specificity was significantly lower in the first screening round (84.6%, 95% CI 83.6–85.7) than in subsequent screening rounds (91.1%, 95% CI 90.6–91.7), p < 0.001. Cancer detection rates (CDRs) and as a result positive predictive values were strongly dependent on type of screening round, risk group and patient age. CDRs ranged from 43.5‰ (95% CI 29.8–62.9) for the first screening round in BRCA2 carriers to 2.9‰ (95% CI 1.3–6.3) for subsequent screening rounds in high-risk non-carriers in the age group 30 to 39 years. Conclusions: High-risk screening with MRI was successfully implemented in the GC-HBOC with high sensitivity and specificity. Risk prediction and inclusion criteria in high-risk non-carriers need to be adjusted to improve CDRs and thus screening efficacy in these patients.
KW - BRCA1 gene
KW - BRCA2 gene
KW - Breast cancer
KW - Early detection of cancer
KW - Hereditary breast and ovarian cancer syndrome
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=85061295362&partnerID=8YFLogxK
U2 - 10.1007/s10549-019-05152-9
DO - 10.1007/s10549-019-05152-9
M3 - Article
C2 - 30725383
AN - SCOPUS:85061295362
SN - 0167-6806
VL - 175
SP - 217
EP - 228
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -